Status:
UNKNOWN
Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation
Lead Sponsor:
Schiano, Thomas D., MD
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Icahn School of Medicine at Mount Sinai
Conditions:
Hepatitis C Virus
Liver Transplantation
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of this study is to measure intrahepatic HCV RNA levels at the time of liver transplantation in patients receiving antiviral therapy while on the liver transplant waiting list. This will e...
Eligibility Criteria
Inclusion
- Patients age 18-80 with chronic HCV on the liver transplant waiting list may be eligible for participation
- The following subjects will be enrolled:
- Patients undergoing liver transplantation who are documented HCV viral load undetectable while on antiviral therapy
- Patients receiving anti-viral therapy and who have a detectable HCV viral load
- Patients not currently receiving antiviral therapy and are HCV PCR (+) will be included and serve as a comparison group
Exclusion
- Patients who are co-infected with HIV and/or HBV will not be included
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01836718
Start Date
June 1 2013
End Date
June 1 2018
Last Update
January 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai School of Medicine Recanati/Miller Transplantation Institute
New York, New York, United States, 10029